Derma Sciences Reports Fourth Quarter, Year-End Result...(Year ended December 31 ...),Health

Date:4/1/2009

Year ended December 31 2008 2007 Net Sales $50,199,428 $34,135,401 Cost of sales 35,289,684 22,530,986 Gross Profit 14,909,744 11,604,415 Operating expenses Selling, general and administrative 17,196,863 11,885,368 Research and development 653,326 993,069 Total operating expenses 17,850,189 12,878,437 Operating loss (2,940,445) (1,274,022) Other expense, net: Interest expense 940,148 413,992 Loss on debt extinguishment -- 256,628 Other expense, net 22,529 77,929 Total other expense, net 962,677 748,549 Loss before provision for income taxes (3,903,122) (2,022,571) Provision for income taxes 58,815 262,034 Net Loss $(3,961,937) $(2,284,605) Net loss per common share - basic and diluted $(0.10) $(0.09) Shares used in computing net loss per common share - basic and diluted 38,606,779 26,523,541 DERMA SCIENCES, INC. AND SUBSIDIARIES Consolidated Balance Sheets December 31 ASSETS 2008 2007 Current Assets Cash and cash equivalents $391,038 $577,096 Accounts receivable, net 3,892,523 3,667,119 Inventories 12,423,042 9,935,977 Prepaid expenses and other
'/>"/>

SOURCE Derma Sciences, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine news :

1. Derma Sciences to Report 2008 Fourth Quarter and Year-End Results on April 1, 2009
2. Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced
3. Wendy E. Roberts, MD, Named 2009-2010 President of the Womens Dermatologic Society
4. Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil.
5. Palomar Medical to Debut New Devices and a More Powerful Platform at the American Academy of Dermatology Annual Meeting
6. Aesthera Announces Breakthrough Innovations at 2009 American Academy of Dermatology (AAD) Meeting
7. The Texas Institute of Dermatology Team Finds Easy-to-Apply, Topical Drug Just as Good as Injectable Compound for a Disfigurating Skin Infection
8. NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
9. Professional Skin Care Company OrthoNeutrogena Becomes Ortho Dermatologics
10. American Academy of Dermatology Issues New Guidelines For The Management of Psoriasis With Topical Therapies
11. Derma Sciences Gains FDA Clearance for Novel BIOGUARD(TM) Barrier Dressing with NIMBUS(R) Technology